Back to Database
Tirzepatide
FDA ApprovedTirzepatide (Dual GIP/GLP-1 Agonist)
Also known as: Mounjaro, Zepbound
Moderate Risk
Fat Loss
A dual GIP/GLP-1 receptor agonist showing superior weight loss vs semaglutide in head-to-head trials. Up to 20%+ body weight loss.
Benefits
Superior weight loss vs semaglutide (up to 20%+)
Dual mechanism (GIP + GLP-1) for enhanced efficacy
Greater waist circumference reduction
Improved blood sugar control
Reduced cardiovascular risk markers
Strong appetite suppression
Side Effects & Risks
Nausea (common, dose-dependent)moderate
Diarrheamoderate
Constipationmild
Vomitingmoderate
Rare: pancreatitis, gallbladder issuesserious
Dosing Information
Typical Dose
2.5mg weekly escalating to 15mg weekly
Administration
Weekly subcutaneous injection
Cycle Length
Ongoing under physician supervision
Notes
Dose escalation over weeks. No oral tirzepatide in development (molecule too large). Eli Lilly developing orforglipron, a separate oral GLP-1.
Legal Status
FDA Status
FDA-APPROVED (Mounjaro, Zepbound)
Availability
Prescription at standard pharmacies
WADA Status
Not currently banned
Evidence
Evidence LevelVery High
NEJM head-to-head trial vs semaglutide showing superiority at week 72.
Where to Buy
Available from verified suppliers
NovaCompound Rx Verified4.9
View Supplier Compounded Tirzepatide Injection
Pre-MixedPurity: 99%+
COA Available Third-Party Tested Requires PrescriptionIn Stock